# A Study of Ruxolitinib Phosphate Cream When Applied to Patients With Plaque Psoriasis

> **NCT00820950** · PHASE2 · COMPLETED · sponsor: **Incyte Corporation** · enrollment: 29 (actual)

## Conditions studied

- Psoriasis

## Interventions

- **DRUG:** Ruxolitinib phosphate cream
- **DRUG:** Dovonex® calcipotriene 0.005%
- **DRUG:** Diprolene® AF betamethasone dipropionate 0.05% cream.
- **DRUG:** Placebo cream
- **DRUG:** Ruxolitinib phosphate cream
- **DRUG:** Ruxolitinib phosphate cream

## Key facts

- **NCT ID:** NCT00820950
- **Lead sponsor:** Incyte Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-05-31
- **Primary completion:** 2009-01-31
- **Final completion:** 2009-04-30
- **Target enrollment:** 29 (ACTUAL)
- **Last updated:** 2022-02-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00820950

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00820950, "A Study of Ruxolitinib Phosphate Cream When Applied to Patients With Plaque Psoriasis". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT00820950. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*